CL2018001716A1 - Reguladores del cftr y métodos para su uso - Google Patents

Reguladores del cftr y métodos para su uso

Info

Publication number
CL2018001716A1
CL2018001716A1 CL2018001716A CL2018001716A CL2018001716A1 CL 2018001716 A1 CL2018001716 A1 CL 2018001716A1 CL 2018001716 A CL2018001716 A CL 2018001716A CL 2018001716 A CL2018001716 A CL 2018001716A CL 2018001716 A1 CL2018001716 A1 CL 2018001716A1
Authority
CL
Chile
Prior art keywords
methods
cfr
regulators
disorders
cftr
Prior art date
Application number
CL2018001716A
Other languages
English (en)
Inventor
Alan Verkman
Marc H Levin
Onur Cil
Mark J Kurth
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of CL2018001716A1 publication Critical patent/CL2018001716A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

EN EL PRESENTE DOCUMENTO SE PROPORCIONAN COMPUESTOS QUE ACTIVAN EL CFTR Y MÉTODOS PARA TRATAR EL ESTREÑIMIENTO, TRASTORNOS DE SEQUEDAD DE OJOS, Y OTRAS ENFERMEDADES Y TRASTORNOS.
CL2018001716A 2015-12-24 2018-06-21 Reguladores del cftr y métodos para su uso CL2018001716A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562387579P 2015-12-24 2015-12-24
US201662376808P 2016-08-18 2016-08-18

Publications (1)

Publication Number Publication Date
CL2018001716A1 true CL2018001716A1 (es) 2018-10-26

Family

ID=59091221

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001716A CL2018001716A1 (es) 2015-12-24 2018-06-21 Reguladores del cftr y métodos para su uso

Country Status (18)

Country Link
US (2) US11084795B2 (es)
EP (2) EP4071140A1 (es)
JP (2) JP6938509B2 (es)
KR (1) KR20180101416A (es)
CN (1) CN108699040B (es)
AU (1) AU2016377785B2 (es)
BR (1) BR112018012934B1 (es)
CA (1) CA3009534A1 (es)
CL (1) CL2018001716A1 (es)
CO (1) CO2018007236A2 (es)
DK (1) DK3394046T3 (es)
ES (1) ES2913051T3 (es)
IL (1) IL260212B (es)
PL (1) PL3394046T3 (es)
PT (1) PT3394046T (es)
RU (1) RU2730855C2 (es)
WO (1) WO2017112950A1 (es)
ZA (1) ZA201804229B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112951A1 (en) 2015-12-24 2017-06-29 The Regents Of The University Of California Cftr regulators and methods of use thereof
PT3394046T (pt) * 2015-12-24 2022-04-05 Univ California Reguladores de cftr e seus métodos de uso
EP3672598A4 (en) 2017-08-24 2021-04-28 The Regents of The University of California OCULAR PHARMACEUTICAL COMPOSITIONS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
ZA794209B (en) * 1978-08-15 1980-07-30 Fisons Ltd Pharmaceutically active heterocyclic compounds
US4181724A (en) 1978-09-11 1980-01-01 The Upjohn Company Quinoxalinone compounds useful for expanding the lumina or air passages in mammals
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
FR2653430B1 (fr) 1989-10-23 1991-12-20 Pf Medicament Nouveaux derives de dihydro-1,2 oxo-2 quinoxalines, leur preparation et leur application en therapeutique.
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO1994011355A1 (en) * 1992-11-19 1994-05-26 Dainippon Pharmaceutical Co., Ltd. 3,4-dihydro-1-(2-hydroxyphenyl)-2(1h)-quinoxalinone derivative and related compound
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1999050254A1 (en) * 1998-03-31 1999-10-07 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
DE102004023332A1 (de) * 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
US8263607B2 (en) * 2007-05-22 2012-09-11 Astellas Pharma Inc. 1-substituted tetrahydroisoquinoline compound
US8415352B2 (en) * 2008-03-05 2013-04-09 MERCK Patent Gesellschaft mit beschränkter Haftung Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
JP5645834B2 (ja) * 2008-10-23 2014-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス制御因子の修飾因子
AU2013365827A1 (en) * 2012-12-19 2015-07-09 Novartis Ag Tricyclic compounds as CFTR inhibitors
WO2015168079A1 (en) * 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
PT3394046T (pt) 2015-12-24 2022-04-05 Univ California Reguladores de cftr e seus métodos de uso

Also Published As

Publication number Publication date
CO2018007236A2 (es) 2018-07-19
EP4071140A1 (en) 2022-10-12
EP3394046A4 (en) 2019-06-19
CA3009534A1 (en) 2017-06-29
CN108699040B (zh) 2021-08-10
DK3394046T3 (da) 2022-04-04
PT3394046T (pt) 2022-04-05
RU2730855C2 (ru) 2020-08-26
BR112018012934B1 (pt) 2023-11-07
EP3394046B1 (en) 2022-03-09
IL260212B (en) 2021-08-31
JP7297828B2 (ja) 2023-06-26
RU2018126957A3 (es) 2020-02-28
AU2016377785A2 (en) 2018-08-23
ES2913051T3 (es) 2022-05-31
BR112018012934A2 (pt) 2018-12-11
AU2016377785B2 (en) 2021-07-01
KR20180101416A (ko) 2018-09-12
US11084795B2 (en) 2021-08-10
AU2016377785A1 (en) 2018-07-12
US20190031622A1 (en) 2019-01-31
IL260212A (en) 2018-07-31
RU2018126957A (ru) 2020-01-27
CN108699040A (zh) 2018-10-23
EP3394046A1 (en) 2018-10-31
WO2017112950A1 (en) 2017-06-29
ZA201804229B (en) 2021-10-27
US20210347742A1 (en) 2021-11-11
PL3394046T3 (pl) 2022-06-13
JP2018538352A (ja) 2018-12-27
JP6938509B2 (ja) 2021-09-22
JP2021185186A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
BR112018012138A2 (pt) moléculas de anticorpo para pd-1 e usos das mesmas
MY197345A (en) Antibody molecules to april and uses thereof
PH12016501763A1 (en) Multispecific antibodies
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
TN2016000272A1 (en) Antibody molecules to pd-1 and uses thereof.
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
MX2016013280A (es) Composiciones topicas para el alivio del dolor, manufactura y uso.
CL2016002257A1 (es) Anticuerpos anti-mcam y métodos de uso asociados
CL2018001714A1 (es) Reguladores del cftr y métodos para su uso
TR201900124T4 (tr) Dispersiyon Reçineleri
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112016026544A2 (pt) métodos para inibir a necroptose
CL2018001715A1 (es) Reguladores del cftr y métodos para su uso
CL2018001716A1 (es) Reguladores del cftr y métodos para su uso
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
DOP2016000263A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
MX2017006807A (es) Extractos titulados de cynara scolymus y usos de los mismos.
UA114708U (uk) Тяговий привід електробуса